Get notified when SLN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Emphasis of Matter (new) — The auditor's report flags a going-concern-type issue: the company needs more financing to continue its R&D.
Silence Therapeutics prices $175M ADS offering at $13.50 per share; net proceeds $164M
Filed August 12, 2026 · ~1 min read
Key Changes
-
high
Silence Therapeutics is offering 12,962,963 ADSs at $13.50 per share, each representing three ordinary shares, with a 30-day underwriter option for 1,944,444 additional ADSs.
The Offering verify on EDGAR → -
high
The company estimates net proceeds of $164.0 million from the base offering, or $188.7 million if the underwriters fully exercise their option.
Use of Proceeds verify on EDGAR → -
high
Proceeds will fund continued clinical development of product candidates and general corporate purposes, with cash runway expected into 2030.
Use of Proceeds verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (GIS 10-Q) is open in full — no account needed.
Partner
Trade SLN commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify